Supernus Pharmaceuticals, Inc.
US ˙ NasdaqGM ˙ US8684591089

SecuritySUPN / Supernus Pharmaceuticals, Inc.
InstitutionQUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series
Latest Disclosed Ownership93,475 shares
Latest Disclosed Value $ 2,946,332
QUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series reports 8.64% increase in ownership of SUPN / Supernus Pharmaceuticals, Inc.

On August 26, 2025 - QUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series filed a NPORT-P form disclosing ownership of 93,475 shares of Supernus Pharmaceuticals, Inc. (US:SUPN) valued at $2,946,332 USD as of June 30, 2025. The entity filed a previous NPORT-P on May 28, 2025 disclosing 86,041 shares of Supernus Pharmaceuticals, Inc.. This represents a change in shares of 8.64% during the quarter. The current value of the position is $4,183,006 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2025-08-26 2025-06-30 NP Supernus Pharmaceuticals EC US8684591089 93,475 7,434 8.64 2,946 4.58 0.0662
2025-05-28 2025-03-31 NP Supernus Pharmaceuticals EC US8684591089 86,041 1,369 1.62 2,818 -7.97 0.0676
2025-02-25 2024-12-31 NP Supernus Pharmaceuticals EC US8684591089 84,672 -13,987 -14.18 3,062 -0.49 0.0669
2024-11-26 2024-09-30 NP Supernus Pharmaceuticals EC US8684591089 98,659 5,232 5.60 3,076 23.09 0.0582
2024-08-26 2024-06-30 NP Supernus Pharmaceuticals EC US8684591089 93,427 7,182 8.33 2,499 -15.03 0.0509
2024-05-28 2024-03-31 NP Supernus Pharmaceuticals EC US8684591089 86,245 -3,255 -3.64 2,942 13.55 0.0614
2024-02-26 2023-12-31 NP Supernus Pharmaceuticals EC US8684591089 89,500 6,149 7.38 2,590 12.76 0.0553
2023-11-28 2023-09-30 NP Supernus Pharmaceuticals EC US8684591089 83,351 -1,437 -1.69 2,298 -9.85 0.0600
2023-08-25 2023-06-30 NP Supernus Pharmaceuticals EC US8684591089 84,788 5,832 7.39 2,549 -10.91 0.0604
2023-05-26 2023-03-31 NP Supernus Pharmaceuticals EC US8684591089 78,956 1,634 2.11 2,861 3.70 0.0762
2023-02-24 2022-12-31 NP Supernus Pharmaceuticals EC US8684591089 77,322 -3,109 -3.87 2,758 1.32 0.0759
2022-11-25 2022-09-30 NP Supernus Pharmaceuticals EC US8684591089 80,431 3,760 4.90 2,723 22.78 0.0780
2022-08-25 2022-06-30 NP Supernus Pharmaceuticals EC US8684591089 76,671 118 0.15 2,217 -10.39 0.0612
2022-05-26 2022-03-31 NP Supernus Pharmaceuticals EC US8684591089 76,553 1,901 2.55 2,474 13.69 0.0576
2022-02-25 2021-12-31 NP Supernus Pharmaceuticals EC US8684591089 74,652 0 0.00 2,177 9.35 0.0472
2021-11-24 2021-09-30 NP Supernus Pharmaceuticals EC US8684591089 74,652 0 0.00 1,991 -13.40 0.0439
2021-08-26 2021-06-30 NP Supernus Pharmaceuticals EC US8684591089 74,652 14 0.02 2,299 17.60 0.0493
2021-05-27 2021-03-31 NP Supernus Pharmaceuticals EC US8684591089 74,638 -3,888 -4.95 1,954 -1.06 0.0443
2021-02-25 2020-12-31 NP Supernus Pharmaceuticals EC US8684591089 78,526 0 0.00 1,976 20.72 0.0506
2020-11-25 2020-09-30 NP Supernus Pharmaceuticals EC US8684591089 78,526 -4,239 -5.12 1,636 -16.74 0.0525
2020-08-27 2020-06-30 NP Supernus Pharmaceuticals EC US8684591089 82,765 2,854 3.57 1,966 36.74 0.0643
2020-06-01 2020-03-31 NP Supernus Pharmaceuticals EC US8684591089 79,911 3,779 4.96 1,438 -20.39 0.0588
2020-02-27 2019-12-31 NP Supernus Pharmaceuticals EC 868459108 76,132 847 1.13 1,806 -12.72 0.0543
2019-11-27 2019-09-30 NP Supernus Pharmaceuticals EC US8684591089 75,285 75,285 2,069 0.0684
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.